Top

Inflammation Research

Published in:

Open Access 29-06-2023 | Glucocorticoid | Original Research Paper

The regulation of TRPA1 expression and function by Th1 and Th2-type inflammation in human A549 lung epithelial cells

Authors: Samu Luostarinen, Mari Hämäläinen, Antti Pemmari, Eeva Moilanen

Published in: Inflammation Research | Issue 7/2023

Abstract

Background

Transient Receptor Potential Ankyrin 1 (TRPA1) is a cation channel that mediates pain, itch, cough, and neurogenic inflammation in response to pungent compounds such as acrolein in cigarette smoke. TRPA1 is also activated by endogenous factors and promotes inflammation in asthma models. We have recently shown that TRPA1 is upregulated by inflammatory cytokines in A549 human lung epithelial cells. Here, we explored the effects of Th1 and Th2-type inflammation on TRPA1.

Methods and results

TRPA1 expression and function was studied in A549 human lung epithelial cells. To induce inflammation, the cells were exposed to a combination of cytokines TNF-α and IL-1β; and to model Th1 or Th2-type responses, IFN-γ or IL-4/IL-13 was added, respectively. TRPA1 expression (measured by RT-PCR and Western blot) and function (assessed by Fluo-3AM intracellular calcium measurement) was enhanced under the influence of TNF-α + IL-1β. IFN-γ further enhanced TRPA1 expression and function, whereas IL-4 and IL-13 suppressed them. The effects of IFN-γ and IL-4 on TRPA1 expression were reversed by the Janus kinase (JAK) inhibitors baricitinib and tofacitinib, and those of IL-4 also by the STAT6 inhibitor AS1517499. The glucocorticoid dexamethasone downregulated TRPA1 expression, whereas the PDE4 inhibitor rolipram had no effect. Under all conditions, TRPA1 blockade was found to reduce the production of LCN2 and CXCL6.

Conclusions

TRPA1 expression and function in lung epithelial cells was upregulated under inflammatory conditions. IFN-γ further increased TRPA1 expression while IL-4 and IL-13 suppressed that in a JAK-STAT6 dependent manner which is novel. TRPA1 also modulated the expression of genes relevant to innate immunity and lung disease. We propose that the paradigm of Th1 and Th2 inflammation is a major determinant of TRPA1 expression and function, which should be considered when targeting TRPA1 for pharmacotherapy in inflammatory (lung) disease.

Available only for authorised users

Talavera K, Startek JB, Alvarez-Collazo J, Boonen B, Alpizar YA, Sanchez A, et al. Mammalian transient receptor potential TRPA1 channels: from structure to disease. Physiol Rev. 2020. https://doi.org/10.1152/physrev.00005.2019.CrossRefPubMed

Koivisto A-P, Belvisi MG, Gaudet R, Szallasi A. Advances in TRP channel drug discovery: from target validation to clinical studies. Nat Rev Drug Discov. 2021. https://doi.org/10.1038/s41573-021-00268-4.CrossRefPubMedPubMedCentral

Jordt S-E, Bautista DM, Chuang H, McKemy DD, Zygmunt PM, Högestätt ED, et al. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nat Publ Group. 2004;427:260–5.

Andrè E, Campi B, Materazzi S, Trevisani M, Amadesi S, Massi D, et al. Cigarette smoke–induced neurogenic inflammation is mediated by α, β-unsaturated aldehydes and the TRPA1 receptor in rodents. J of Clin Invest. 2008. https://doi.org/10.1172/JCI34886.CrossRef

Takahashi N, Mizuno Y, Kozai D, Yamamoto S, Kiyonaka S, Shibata T, et al. Molecular characterization of TRPA1 channel activation by cysteine-reactive inflammatory mediators. Channels Taylor & Francis. 2008;2:287–98.

Andersson DA, Gentry C, Moss S, Bevan S. Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci Soc Neurosci. 2008;28:2485–94.CrossRef

Bessac BF, Sivula M, von Hehn CA, Escalera J, Cohn L, Jordt S-E. TRPA1 is a major oxidant sensor in murine airway sensory neurons. J Clin Invest. 2008;118:1899–910.PubMedPubMedCentralCrossRef

Taylor-Clark TE, Ghatta S, Bettner W, Undem BJ. Nitrooleic acid, an endogenous product of nitrative stress, activates nociceptive sensory nerves via the direct activation of TRPA1. Mol Pharmacol ASPET. 2009;75:820–9.CrossRef

Nummenmaa E, Hamalainen M, Moilanen LJ, Paukkeri EL, Nieminen RM, Moilanen T, et al. Transient receptor potential ankyrin 1 (TRPA1) is functionally expressed in primary human osteoarthritic chondrocytes. Arthritis Res Ther England. 2016;18:184–5.

10.

Atoyan R, Shander D, Botchkareva N, v. Non-Neuronal Expression of Transient Receptor Potential Type A1 (TRPA1) in Human Skin. J Investigat Dermatol. 2009;129:2312–5.CrossRef

11.

Jain A, Brnneke S, Kolbe L, Stb F, Wenck H, Neufang G. TRP-channel-specific cutaneous eicosanoid release patterns. Pain Elsevier. 2011;152:2765–72.CrossRef

12.

Luostarinen S, Hämäläinen M, Moilanen E. Transient receptor potential ankyrin 1 (TRPA1)-an inflammation-induced factor in human HaCaT Keratinocytes. Int J Mol Sci. 2021;22(7):3322.PubMedPubMedCentralCrossRef

13.

Nassini R, Pedretti P, Moretto N, Fusi C, Carnini C, Facchinetti F, et al. Transient receptor potential ankyrin 1 channel localized to non-neuronal airway cells promotes non-neurogenic inflammation. PLoS ONE. 2012;7: e42454.PubMedPubMedCentralCrossRef

14.

Mukhopadhyay I, Gomes P, Aranake S, Shetty M, Karnik P, Damle M, et al. Expression of functional TRPA1 receptor on human lung fibroblast and epithelial cells. J Recep Signal Transd. 2011;31:350–8.CrossRef

15.

Luostarinen S, Hämäläinen M, Hatano N, Muraki K, Moilanen E. The inflammatory regulation of TRPA1 expression in human A549 lung epithelial cells. Pulm Pharmacol Ther. 2021;70:102059.PubMedCrossRef

16.

Wang S, Shi P, Wang Y. TRPA1 ion channels in vagal afferent nerves contribute to ventilator-induced lung injury in a rat model. Gen Physiol Biophys. 2013;32:389–94.PubMedCrossRef

17.

Lin A-H, Liu M-H, Ko H-K, Perng D-W, Lee T-S, Kou YR. Lung Epithelial TRPA1 transduces the extracellular ROS into transcriptional regulation of lung inflammation induced by cigarette smoke: the role of influxed Ca ²⁺. Mediators Inflamm. 2015;2015:1–16.

18.

Prandini P, de Logu F, Fusi C, Provezza L, Nassini R, Montagner G, et al. Transient receptor potential ankyrin 1 channels modulate inflammatory response in respiratory cells from patients with cystic fibrosis. Am J Respir Cell Mol Biol. 2016;55:645–56.PubMedCrossRef

19.

Wang M, Zhang Y, Xu M, Zhang H, Chen Y, Chung KF, et al. Roles of TRPA1 and TRPV1 in cigarette smoke -induced airway epithelial cell injury model. Free Radic Biol Med. 2019;134:229–38.PubMedCrossRef

20.

Ko H-K, Lin A-H, Perng D-W, Lee T-S, Kou YR. Lung epithelial TRPA1 Mediates lipopolysaccharide-induced lung inflammation in bronchial epithelial cells and mice. Front Physiol. 2020. https://doi.org/10.3389/fphys.2020.596314.CrossRefPubMedPubMedCentral

21.

Yap JMG, Ueda T, Takeda N, Fukumitsu K, Fukuda S, Uemura T, et al. An inflammatory stimulus sensitizes TRPA1 channel to increase cytokine release in human lung fibroblasts. Cytokine. 2020;129: 155027.PubMedCrossRef

22.

Fang Z, Yi F, Peng Y, Zhang J, (Jim), Zhang L, Deng Z, et al. Inhibition of TRPA1 reduces airway inflammation and hyperresponsiveness in mice with allergic rhinitis. FASEB J. 2021. https://doi.org/10.1096/fj.201902627R.CrossRefPubMed

23.

Nummenmaa E, Hämäläinen M, Pemmari A, Moilanen LJ, Tuure L, Nieminen RM, et al. Transient receptor potential ankyrin 1 (TRPA1) Is involved in upregulating interleukin-6 expression in osteoarthritic chondrocyte models. Int J Mol Sci. 2020;22:87.PubMedPubMedCentralCrossRef

24.

Hajna Z, Csekő K, Kemény Á, Kereskai L, Kiss T, Perkecz A, et al. Complex regulatory role of the TRPA1 receptor in acute and chronic airway inflammation mouse models. Int J Mol Sci. 2020;21:4109.PubMedPubMedCentralCrossRef

25.

Caceres AI, Brackmann M, Elia MD, Bessac BF, del Camino D, D’Amours M, et al. A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. Proc Natl Acad Sci. 2009;106:9099–104.PubMedPubMedCentralCrossRef

26.

Wu Y, You H, Ma P, Li L, Yuan Y, Li J, et al. Role of transient receptor potential ion channels and evoked levels of neuropeptides in a formaldehyde-induced model of asthma in BALB/c mice. PLoS ONE. 2013;8:e62827.PubMedPubMedCentralCrossRef

27.

Li M, Fan X, Yue Q, Hu F, Zhang Y, Zhu C. The neuro-immune interaction in airway inflammation through TRPA1 expression in CD4+ T cells of asthmatic mice. Int Immunopharmacol. 2020;86: 106696.PubMedCrossRef

28.

Balestrini A, Joseph V, Dourado M, Reese RM, Shields SD, Rougé L, et al. A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment. J Exp Med. 2021. https://doi.org/10.1084/jem.20201637.CrossRefPubMedPubMedCentral

29.

Sun Y, Liu M, Fan X, Zhou L, Li M, Hu F, et al. Effects of cigarette smoke on the aggravation of ovalbumin-induced asthma and the expressions of TRPA1 and tight junctions in mice. Mol Immunol. 2021;135:62–72.PubMedCrossRef

30.

Hatano N, Itoh Y, Suzuki H, Muraki Y, Hayashi H, Onozaki K, et al. Hypoxia-inducible factor-1alpha (HIF1alpha) switches on transient receptor potential ankyrin repeat 1 (TRPA1) gene expression via a hypoxia response element-like motif to modulate cytokine release. J Biol Chem United States. 2012;287:31962–72.CrossRef

31.

Meng J, Wang J, Steinhoff M, Dolly JO. TNFα induces co-trafficking of TRPV1/TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18–1/syntaxin1/SNAP-25 mediated fusion. Sci Rep. 2016;6:21226.PubMedPubMedCentralCrossRef

32.

Nugent M, Yusef YR, Meng J, Wang J, Dolly JO. A SNAP-25 cleaving chimera of botulinum neurotoxin /A and /E prevents TNFα−induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons. Neuropharmacology. 2018;138:257–66.PubMedCrossRef

33.

Takahashi K, Ohta T. Membrane translocation of transient receptor potential ankyrin 1 induced by inflammatory cytokines in lung cancer cells. Biochem Biophys Res Commun. 2017;490:587–93.PubMedCrossRef

34.

Schmidt M, Dubin AE, Petrus MJ, Earley TJ, Patapoutian A. Nociceptive signals induce trafficking of TRPA1 to the plasma membrane. Neuron Elsevier. 2009;64:498–509.CrossRef

35.

Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron Elsevier. 2004;41:849–57.CrossRef

36.

Dai Y, Wang S, Tominaga M, Yamamoto S, Fukuoka T, Higashi T, et al. Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain. J Clin Invest United States. 2007;117:1979–87.CrossRef

37.

Wang S, Dai Y, Fukuoka T, Yamanaka H, Kobayashi K, Obata K, et al. Phospholipase C and protein kinase A mediate bradykinin sensitization of TRPA1: a molecular mechanism of inflammatory pain. Brain. 2008;131:1241–51.PubMedCrossRef

38.

Wilson SR, Th L, Batia LM, Beattie K, Katibah GE, McClain SP, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell. 2013;155:285–95.PubMedPubMedCentralCrossRef

39.

Malin S, Molliver D, Christianson JA, Schwartz ES, Cornuet P, Albers KM, et al. TRPV1 and TRPA1 function and modulation are target tissue dependent. J Neurosci Soc Neurosci. 2011;31:10516–28.CrossRef

40.

Nummenmaa E, Hämäläinen M, Moilanen LJ, Moilanen T, Vuolteenaho K, Moilanen E. TRPA1 expression is downregulated by dexamethasone and aurothiomalate in human chondrocytes: TRPA1 as a novel factor and drug target in arthritis. RMD Open. 2017;3:e000556.PubMedPubMedCentralCrossRef

41.

Wan YY. Multi-tasking of helper T cells. Immunology. 2010;130:166–71.PubMedPubMedCentralCrossRef

42.

Geginat J, Paroni M, Maglie S, Alfen JS, Kastirr I, Gruarin P, et al. Plasticity of human CD4 T cell subsets. Front Immunol. 2014. https://doi.org/10.3389/fimmu.2014.00630.CrossRefPubMedPubMedCentral

43.

Holgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. Nat Rev Dis Primers. 2015;1:15025.PubMedPubMedCentralCrossRef

44.

Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. The Lancet. 2018;391:783–800.CrossRef

45.

Kuruvilla ME, Lee FE-H, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56:219–33.PubMedPubMedCentralCrossRef

46.

Moilanen LJ, Hamalainen M, Lehtimaki L, Nieminen RM, Muraki K, Moilanen E. Pinosylvin Inhibits TRPA1-induced calcium influx in vitro and trpa1-mediated acute paw inflammation in vivo. Basic Clin Pharmacol Toxicol England. 2016;118:238–42.CrossRef

47.

Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18:545–58.PubMedPubMedCentralCrossRef

48.

Junttila IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;9:888.PubMedPubMedCentralCrossRef

49.

Nagashima S, Yokota M, Nakai E, Kuromitsu S, Ohga K, Takeuchi M, et al. Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors. Bioorg Med Chem. 2007;15:1044–55.PubMedCrossRef

50.

Li H, Zuo J, Tang W. Phosphodiesterase-4 Inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018. https://doi.org/10.3389/fphar.2018.01048.CrossRefPubMedPubMedCentral

51.

Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13:290–314.PubMedPubMedCentralCrossRef

52.

Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133–45.PubMedPubMedCentralCrossRef

53.

Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;M3379.

54.

Proost P, de Wolf-Peeters C, Conings R, Opdenakker G, Billiau A, van Damme J. Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO IP-10 and IL-8. J Immunol. 1993;150:1000–10.PubMedCrossRef

55.

Proost P, Wuyts A, Conings R, Lenaerts JP, Billiau A, Opdenakker G, et al. Human and bovine granulocyte chemotactic protein-2: complete amino acid sequence and functional characterization as chemokines. Biochemistry. 1993;32:10170–7.PubMedCrossRef

56.

Wuyts A, van Osselaer N, Haelens A, Samson I, Herdewijn P, Ben-Baruch A, et al. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors cxcr1 and cxcr2 and in vivo inflammatory properties. Biochemistry. 1997;36:2716–23.PubMedCrossRef

57.

Russo RC, Garcia CC, Teixeira MM, Amaral FA. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 2014;10:593–619.PubMedCrossRef

58.

Jovic S, Linge HM, Shikhagaie MM, Olin AI, Lannefors L, Erjefält JS, et al. The neutrophil-recruiting chemokine GCP-2/CXCL6 is expressed in cystic fibrosis airways and retains its functional properties after binding to extracellular DNA. Mucosal Immunol. 2016;9:112–23.PubMedCrossRef

59.

Besnard A-G, Struyf S, Guabiraba R, Fauconnier L, Rouxel N, Proost P, et al. CXCL6 antibody neutralization prevents lung inflammation and fibrosis in mice in the bleomycin model. J Leukoc Biol. 2013;94:1317–23.PubMedCrossRef

60.

Guardado S, Ojeda-Juárez D, Kaul M, Nordgren TM. Comprehensive review of lipocalin 2-mediated effects in lung inflammation. Am J Physiol-Lung Cell Mole Physiol. 2021;321:L726–33.CrossRef

61.

Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432:917–21.PubMedCrossRef

62.

Schroll A, Eller K, Feistritzer C, Nairz M, Sonnweber T, Moser PA, et al. Lipocalin-2 ameliorates granulocyte functionality. Eur J Immunol. 2012;42:3346–57.PubMedCrossRef

63.

Shao S, Cao T, Jin L, Li B, Fang H, Zhang J, et al. Increased Lipocalin-2 contributes to the pathogenesis of psoriasis by modulating neutrophil chemotaxis and cytokine secretion. J Invest Dermatol. 2016;136:1418–28.PubMedCrossRef

64.

Wang Q, Li S, Tang X, Liang L, Wang F, Du H. Lipocalin 2 protects against escherichia coli infection by modulating neutrophil and macrophage function. Front Immunol. 2019. https://doi.org/10.3389/fimmu.2019.02594.CrossRefPubMedPubMedCentral

65.

Saiga H, Nishimura J, Kuwata H, Okuyama M, Matsumoto S, Sato S, et al. Lipocalin 2-dependent inhibition of mycobacterial growth in alveolar epithelium. J Immunol. 2008;181:8521–7.PubMedCrossRef

66.

Dahl SL, Woodworth JS, Lerche CJ, Cramer EP, Nielsen PR, Moser C, et al. Lipocalin-2 Functions as Inhibitor of Innate Resistance to Mycobacterium tuberculosis. Front Immunol. 2018. https://doi.org/10.3389/fimmu.2018.02717.CrossRefPubMedPubMedCentral

Title: The regulation of TRPA1 expression and function by Th1 and Th2-type inflammation in human A549 lung epithelial cells
Authors: Samu Luostarinen
Mari Hämäläinen
Antti Pemmari
Eeva Moilanen
Publication date: 29-06-2023
Publisher: Springer International Publishing
Keywords: Glucocorticoid
Cytokines
Bronchial Asthma
Published in: Inflammation Research / Issue 7/2023
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-023-01750-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2023

Loss of TRIM24 promotes IL-10 expression via CBP/p300-dependent IFNβ1 transcription during macrophage activation

SHP2: its association and roles in systemic lupus erythematosus

Agomir miRNA-150-5p alleviates pristane-induced lupus by suppressing myeloid dendritic cells activation and inflammation via TREM-1 axis

CTRP12 ameliorates post-myocardial infarction heart failure through down-regulation of cardiac apoptosis, oxidative stress and inflammation by influencing the TAK1-p38 MAPK/JNK pathway

Exosomal MiR-381 from M2-polarized macrophages attenuates urethral fibroblasts activation through YAP/GLS1-regulated glutaminolysis

CaMKK2 alleviates myocardial ischemia/reperfusion injury by inhibiting oxidative stress and inflammation via the action on the AMPK-AKT-GSK-3β/Nrf2 signaling cascade

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials